Quick Answer
CorMedix Inc. reported R&D Expense of $19.33 million for fiscal year 2025.
CorMedix Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.33M | +390.4% |
| 2024 | $3.94M | -70.0% |
| 2023 | $13.16M | +23.2% |
| 2022 | $10.68M | -18.7% |
| 2021 | $13.13M | -1.8% |
| 2020 | $13.38M | +21.0% |
| 2019 | $11.05M | -41.3% |
| 2018 | $18.82M | -23.1% |
| 2017 | $24.49M | +55.6% |
| 2016 | $15.74M | +150.5% |
| 2015 | $6.28M | +376.4% |
| 2014 | $1.32M | +7.5% |
| 2013 | $1.23M | +7.4% |
| 2012 | $1.14M | -72.1% |
| 2011 | $4.10M | -25.4% |
| 2010 | $5.49M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.10M | +601.1% | +108.7% |
| June 30, 2025 | $2.44M | +275.2% | -23.5% |
| March 31, 2025 | $3.19M | +281.2% | +339.1% |
| September 30, 2024 | $727.1K | -72.7% | +11.7% |
| June 30, 2024 | $651.0K | -86.4% | -22.3% |
| March 31, 2024 | $837.4K | -75.4% | -68.6% |
| September 30, 2023 | $2.66M | +13.9% | -44.4% |
| June 30, 2023 | $4.79M | +49.4% | +40.7% |
- CorMedix Inc. showed an increase of +390.4% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, CorMedix Inc.’s r&d expense has grown by 251.9% (from $5.49 million to $19.33 million).
- The most recent figure is from CorMedix Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: